The Trump Administration says AHPs will provide small businesses with more choices, access, and coverage options. Here’s what you need to know.
An RFI presents an important opportunity for the healthcare industry to educate CMS on current experiences and challenges.
The law opens up new options for terminally ill patients. But how will it impact managed care organizations?
Healthcare experts weigh in on the president’s plan to lower drug prices. Here’s what they said.
The goal is to help ensure that prescription drug marketing information for consumers and healthcare providers is truthful and balanced. Here’s what the agency plans to research.
Experts weigh in on a recent lawsuit against PBMs, whether similar lawsuits will crop up, and the likely outcomes.
About half of states have transitioned at least some Medicaid beneficiaries away from fee-for-service (FFS) drug programs into drug plans integrated with managed care. Our policy analyst shares why he believes more should do so.
Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.
A Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.
This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.